ProMyelocytic Leukemia (PML) tumor suppressor gene plays a key-role in acute immunohistochemical staining and correlated with disease free survival (DFS) and overall survival promyelocytic leukemia pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet. 62 ampullary adenocarcinoma patients (pts) who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was performed by expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly (OS). In 24 tumor specimens (38.7%) PML was classified as absent, in 16 (25.8%) as focally influenced by pathological T stage (P=0.03), lymph nodal involvement (P=0.002) and PML expression (P=0.001). DFS in pts without PML expression was 28.0 months vs 45.1 and 75.5 for pts with focal and diffuse expression, respectively. OS in the group of pts without PML expression, with focal expression and with diffuse expression was 40, 48 and 77 months, respectively (P=0.002). By a multivariate analysis, PML expression was the strongest prognostic factor for TTP (P=0.003) and the only statically significant prognostic factor for OS (P=0.009). Our preliminary data suggest PML as a novel prognostic tool for ampullary cancer pts.
Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients
ADAMO, Vincenzo;
2009-01-01
Abstract
ProMyelocytic Leukemia (PML) tumor suppressor gene plays a key-role in acute immunohistochemical staining and correlated with disease free survival (DFS) and overall survival promyelocytic leukemia pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet. 62 ampullary adenocarcinoma patients (pts) who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was performed by expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly (OS). In 24 tumor specimens (38.7%) PML was classified as absent, in 16 (25.8%) as focally influenced by pathological T stage (P=0.03), lymph nodal involvement (P=0.002) and PML expression (P=0.001). DFS in pts without PML expression was 28.0 months vs 45.1 and 75.5 for pts with focal and diffuse expression, respectively. OS in the group of pts without PML expression, with focal expression and with diffuse expression was 40, 48 and 77 months, respectively (P=0.002). By a multivariate analysis, PML expression was the strongest prognostic factor for TTP (P=0.003) and the only statically significant prognostic factor for OS (P=0.009). Our preliminary data suggest PML as a novel prognostic tool for ampullary cancer pts.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
